Charles River Laboratories International (NYSE:CRL) Releases FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 11.450-11.450 for the period, compared to the consensus estimate of 11.330. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Charles River Laboratories International Price Performance

CRL stock opened at $289.96 on Thursday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a market cap of $13.84 billion, a P/E ratio of -59.43, a P/E/G ratio of 2.80 and a beta of 1.40. The firm’s fifty day moving average is $267.76 and its 200 day moving average is $211.63. Charles River Laboratories International has a 52 week low of $144.26 and a 52 week high of $303.30.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts predict that Charles River Laboratories International will post 11.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CRL. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Royal Bank Of Canada lifted their price target on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Mizuho set a $264.00 price objective on Charles River Laboratories International in a research report on Monday, August 10th. Finally, Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research note on Monday, August 10th. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $273.81.

Insider Activity at Charles River Laboratories International

In related news, EVP Shannon Parisotto sold 2,039 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $294.12, for a total transaction of $599,710.68. Following the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,413,834.84. This represents a 29.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares in the company, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 165,990 shares of company stock valued at $42,606,388 over the last three months. 1.30% of the stock is owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.